Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Price Gap Between Brand And Generic Drugs Widening – Express Scripts

This article was originally published in The Pink Sheet Daily

Executive Summary

In its inaugural Drug Trends Quarterly, Express Scripts finds that prices for branded pharmaceuticals are growing at a faster pace than the Consumer Price Index and the gap between branded and generic drug prices is at its widest point since the pharmacy benefit manager began calculating price indexes for each in 2008.

You may also be interested in...



Drug Expenditures Expected To Rise 1%-3% In 2013 – ASHP

Analysts reporting in the American Journal of Health-System Pharmacy are predicting that across all settings, pharmaceutical expenditures are expected to rise 1%-3% across all settings, with expenditures in the clinic setting increasing 2%-4%. In hospitals, the expected range is from a potential decrease of 0.5% to an increase of 1.5%.

Express Scripts-Medco Merger Closes With No Divestitures Needed

The FTC voted in a split 3-1 vote to close its investigation and allow Express Scripts’ $29.1 billion acquisition of rival PBM Medco to proceed.

Vertex Prices Telaprevir At $49,200 For Course Of Therapy

In addition to setting a premium price over that for Merck's competing boceprevir, Vertex also indicated it still plans to go it alone on U.S. commercialization despite Merck/Roche alliance.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS073558

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel